News
NIH Director Jay Bhattacharya offered an explanation for the cancellation of mRNA vaccine contracts that didn't align with ...
Dealbreaker on MSN1h
BioNTech to Pay $740M-Plus to Settle mRNA Patent Disputes, Smooth $1.25 Billion DealW hen BioNTech agreed to acquire rival messenger RNA company CureVac in a $1.25 billion stock deal earlier this summer, some ...
The Department of Health and Human Services announced Thursday that it will cut nearly half a billion dollars in funding for 22 vaccine development programs, many of which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback